Cargando…
Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study
BACKGROUND: Ovarian cancer (OC) is a heterogeneous gynecological malignancy with a poor prognosis as the majority of patients are diagnosed at an advanced stage. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is recommended for patients who cannot achieve optimal cytore...
Autores principales: | Zhou, Dongchen, Liu, Jiahao, Liu, Ronghua, Li, Huayi, Huang, Yi, Ma, Ding, Hong, Li, Gao, Qinglei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984467/ https://www.ncbi.nlm.nih.gov/pubmed/35402241 http://dx.doi.org/10.3389/fonc.2022.852772 |
Ejemplares similares
-
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
por: Okamoto, Aikou, et al.
Publicado: (2020) -
Hospital of Nantes
Publicado: (1829) -
Nantes : saisie par la culture /
por: Guidet, Thierry, 1954-
Publicado: (2007) -
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)
por: Asano, Hiroshi, et al.
Publicado: (2022) -
Cooling water going into Nant Gobe.
por: Serge Dailler
Publicado: (1997)